Iwan J. P. de Esch

The paper designs miniproteins that selectively block or bias chemokine receptor signaling by targeting CCL25, demonstrating their ability to suppress CCR9 and modulate ACKR4 responses.

This study characterizes VUF16840 as a selective inverse agonist of ACKR3 that inhibits constitutive and chemokine-induced signaling by stabilizing the inactive conformation of the receptor.

This paper characterizes [3H]AZ12464237 as a high-affinity radioligand for the P2Y12 receptor, showing selectivity and utility in in vitro studies.

This paper designs and characterizes the first photoswitchable small-molecule agonist for ACKR3, showing its selectivity and light-controlled activation properties.

The paper presents a large-scale cancer pharmacogenomic screen with 11,576 experiments on 910 drug combinations across 85 cancer cell lines, enabling crowd-sourced prediction of synergistic drug pairs and biomarkers.